Isentress

Isentress is a brand name of raltegravir, approved by the FDA in the following formulation(s):

ISENTRESS (raltegravir potassium - tablet, chewable; oral)

• 
  Manufacturer: MERCK SHARP DOHME
  
  Approval date: December 21, 2011
  
  Strength(s): EQ 100MG BASE ^[RLD], EQ 25MG BASE
  

ISENTRESS (raltegravir potassium - tablet; oral)

• 
  Manufacturer: MERCK SHARP DOHME
  
  Approval date: October 12, 2007
  
  Strength(s): EQ 400MG BASE ^[RLD]

Has a generic version of Isentress been approved?

No. There is currently no therapeutically equivalent version of Isentress available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Isentress. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase
  Patent 7,169,780
  Issued: January 30, 2007
  Inventor(s): Crescenzi; Benedetta & Gardelli; Cristina & Muraglia; Ester & Orvieto; Federica & Pace; Paola & Pescatore; Giovanna & Petrocchi; Alessia & Poma; Marco & Rowley; Michael & Scarpelli; Rita & Summa; Vincenzo & Nizi; Emanuela
  Assignee(s): Istitute Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A.
  N-substituted 5-hydroxypyrimidin-6-one-4-carboxamides of formula (I): are described as inhibitors of HIV integrase and inhibitors of HIV replication, wherein R1, R2, R3 and R4 are defined herein. These compounds are useful in the prevention and treatment of infection by HIV and in the prevention, delay in the onset, and treatment of AIDS. The compounds are employed against HIV infection and AIDS as compounds per se or in the form of pharmaceutically acceptable salts. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of preventing, treating or delaying the onset of AIDS and methods of preventing or treating infection by HIV are also described
  
  Patent expiration dates:
  
  
  • October 3, 2023
    
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  



• 
  N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase
  Patent 7,217,713
  Issued: May 15, 2007
  Inventor(s): Crescenzi; Benedetta & Gardelli; Cristina & Muraglia; Ester & Nizi; Emanuela & Orvieto; Federica & Pace; Paola & Pescatore; Giovanna & Petrocchi; Alessia & Poma; Marco & Rowley; Michael & Scarpelli; Rita & Summa; Vincenzo
  Assignee(s): Istituto Di Richerche Di Biologia Molecolare P. Angeletti S.p.A.
  N-substituted 5-hydroxypyrimidin-6-one-4-carboxamides of formula: are described as inhibitors of HIV integrase and inhibitors of HIV replication, wherein R1, R2, R3 and R4 are defined herein. These compounds are useful in the prevention and treatment of infection by HIV and in the prevention, delay in the onset, and treatment of AIDS. The compounds-are employed against HIV infection and AIDS as compounds per se or in the form of pharmaceutically acceptable salts. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of preventing, treating or delaying the onset of AIDS and methods of preventing or treating infection by HIV are also described.
  
  Patent expiration dates:
  
  
  • October 21, 2022
    
    ✓ 
    Patent use: TREATMENT OF HIV INFECTION
  
  



• 
  N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase
  Patent 7,435,734
  Issued: October 14, 2008
  Inventor(s): Crescenzi; Benedetta & Gardelli; Cristina & Muraglia; Ester & Nizi; Emanuela & Orvieto; Federica & Pace; Paola & Pescatore; Giovanna & Petrocchi; Alessia & Poma; Marco & Rowley; Michael & Scarpelli; Rita & Summa; Vincenzo
  Assignee(s): Istituto di Ricerche di Biologia Molecolare P. Angeletti S.p.A.
  N-substituted 5-hydroxypyrimidin-6-one-4-carboxamides of formula: are described as inhibitors of HIV integrase and inhibitors of HIV replication, wherein R1, R2, R3 and R4 are defined herein. These compounds are useful in the prevention and treatment of infection by HIV and in the prevention, delay in the onset, and treatment of AIDS. The compounds are employed against HIV infection and AIDS as compounds per se or in the form of pharmaceutically acceptable salts. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of preventing, treating or delaying the onset of AIDS and methods of preventing or treating infection by HIV are also described.
  
  Patent expiration dates:
  
  
  • October 21, 2022
    
    ✓ 
    Patent use: INTEGRASE INHIBITION FOR THE TREATMENT OF HIV INFECTION
  
  
  
  • October 21, 2022
    
    ✓ 
    Patent use: TREATMENT OF HIV INFECTION
  
  



• 
  Potassium salt of an HIV integrase inhibitor
  Patent 7,754,731
  Issued: July 13, 2010
  Inventor(s): Belyk; Kevin M. & Morrison; Henry G. & Mahajan; Amar J. & Kumke; Daniel J. & Tung; Hsien-Hsin & Wai; Lawrence & Pruzinsky; Vanessa
  Assignee(s): Merck Sharp & Dohme Corp.
  Potassium salts of Compound A and methods for their preparation are disclosed, wherein Compound A is of formula: Compound A is an HIV integrase inhibitor useful for treating or prophylaxis of HIV infection, for delaying the onset of AIDS, and for treating or prophylaxis of AIDS.
  
  Patent expiration dates:
  
  
  • March 11, 2029
    
    ✓ 
    Patent use: TREATMENT OF HIV INFECTION
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • October 12, 2012 - NEW CHEMICAL ENTITY
  
  
  • December 21, 2014 - NEW PATIENT POPULATION
  
  
  • December 21, 2014 - NEW DOSAGE FORM
  
  

See also...

• Isentress Consumer Information (Drugs.com)
• Isentress Consumer Information (Wolters Kluwer)
• Isentress Consumer Information (Cerner Multum)
• Isentress Advanced Consumer Information (Micromedex)
• Isentress AHFS DI Monographs (ASHP)
• Raltegravir Consumer Information (Wolters Kluwer)
• Raltegravir Consumer Information (Cerner Multum)
• Raltegravir Advanced Consumer Information (Micromedex)
• Raltegravir Potassium AHFS DI Monographs (ASHP)